Previous 10 | Next 10 |
Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan PR Newswire Calliditas announces that it has entered into an agreement with Viatris to bring Nefecon®, a specialty therapy focused...
Calliditas to host fireside chat with its China commercial partner, Everest Medicines PR Newswire STOCKHOLM , Dec. 9, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it will host a fireside chat with its commercial par...
Calliditas Therapeutics ( OTCPK:CLTEF ) ( NASDAQ: CALT ) said China's National Medical Products Administration (NMPA) accepted to review Everest Medicines' new drug application (NDA) for kidney disease drug Nefecon. Calliditas said that Nefecon, if approved, w...
Calliditas' partner Everest Medicine's New Drug Application for Nefecon is accepted by the China NMPA PR Newswire STOCKHOLM , Nov. 15, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today...
Calliditas Therapeutics press release ( NASDAQ: CALT ): Q3 GAAP EPS of SEK 0.21. Revenue of SEK 260.1M (+31.2% Y/Y). Cash amounted to SEK 736.2M and SEK 1,163.8M as of September 30, 2022 and 2021, respectively. "We expect to achieve net sales fr...
Calliditas Therapeutics: Interim Report Q3, 2022 PR Newswire Conditional Marketing Authorization in EU Granted for Kinpeygo ® STOCKHOLM , Nov. 14, 2022 /PRNewswire/ -- "On July 15th the European Commission issued the conditional ...
Key Opinion Leader Fireside Chat with Professor Richard Lafayette on the US IgAN Treatment Landscape PR Newswire STOCKHOLM , Nov. 7, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it will host a Key Opinion Le...
Calliditas Therapeutics' nomination committee composition for the AGM 2023 PR Newswire Calliditas Therapeutics AB (publ.) publishes the nomination committee's composition for the AGM in 2023. STOCKHOLM , Oct. 21, 2022 /PRNewswire/ -- The nominatio...
Kidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO® (budesonide) in IgA Nephropathy PR Newswire STOCKHOLM , Oct. 19, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("C...
Summary The key catalyst for Travere in the near term is the PDUFA date for sparsentan for the treatment of IgA nephropathy in early November. With a positive outcome anticipated, there might not be enough reward to hold the stock into the event. Given the recent slow launches...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB Company Name:
CALT Stock Symbol:
NASDAQ Market:
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy PR Newswire STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Ca...
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis PR Newswire STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) ( STOCKHOLM : CALTX) ("Calliditas") today announced that the Pha...
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatri...